Hepatic encephalopathy: An updated approach from pathogenesis to treatment

Medical Science Monitor

Volumn 17, Issue 2, 2011, Pages

  Toris, Giannakis T ^a   Bikis, Christos N ^a   Tsourouflis, Gerasimos S ^a   Theocharis, Stamatios E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Hepatic encephalopathy; Hyperammonemia; Minimal hepatic encephalopathy; Pathophysiology; Treatment

Indexed keywords

ACARBOSE; ANTIBIOTIC AGENT; AQUAPORIN 4; AST 120; BENZOIC ACID; BUTYRIC ACID DERIVATIVE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUOROURACIL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSE TRANSPORTER 1; GLUTAMATE AMMONIA LIGASE; GLUTAMATE TRANSPORTER; HPN 100; LACTITOL; LACTULOSE; LEVACECARNINE; MANNITOL; METRONIDAZOLE; NARCOTIC AGENT; NEUROTOXIN; NITAZOXANIDE; ORNITHINE ASPARTATE; PHENYLACETIC ACID; PREGNENOLONE; PROBIOTIC AGENT; SALICYLIC ACID; SEDATIVE AGENT; THIAMINE; TRANQUILIZER; UNCLASSIFIED DRUG; VALPROIC ACID;

ACIDEMIA; ACUTE HEPATITIS; ALBUMIN DIALYSIS; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMMONIA BLOOD LEVEL; ARTIFICIAL EMBOLISM; ASCITES; ASTROCYTE; BACTERIAL PERITONITIS; BILE DUCT ATRESIA; BLOOD BRAIN BARRIER; BRAIN LEVEL; CARNITINE DEFICIENCY; CEREBROSPINAL FLUID; CHRONIC LIVER DISEASE; COGNITIVE DEFECT; CONSTIPATION; CYSTIC FIBROSIS; DEFECATION HABIT; DEHYDRATION; DETOXIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTROENCEPHALOGRAM; EVOKED AUDITORY RESPONSE; FEVER; FULMINANT HEPATIC FAILURE; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; HIGH FIBER DIET; HUMAN; HYPERAMMONEMIA; HYPERORNITHINEMIA HYPERAMMONEMIA HOMOCITRULLINURIA SYNDROME; HYPOKALEMIA; HYPONATREMIA; HYPOVOLEMIA; HYPOXIA; INDUCED HYPOTHERMIA; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG INFECTION; LYSINURIC PROTEIN INTOLERANCE; MEDICAL HISTORY; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; MINIMAL HEPATIC ENCEPHALOPATHY; MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PARACENTESIS; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PORTOSYSTEMIC ANASTOMOSIS; PROPIONIC ACIDEMIA; PROTEIN INTAKE; PROTEIN RESTRICTION; PSYCHOLOGIC TEST; PSYCHOMOTOR DISORDER; PYRUVATE CARBOXYLASE DEFICIENCY; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY; RESPIRATORY ALKALOSIS; REVIEW; REYE SYNDROME; SECRETORY PATHWAY; SKIN INFECTION; TERMINAL DISEASE; TOTAL COLON RESECTION; TOXIC HEPATITIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UREA CYCLE DISORDER; UREMIA; URINARY DIVERSION; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION; VIRUS INFECTION; VITAMIN INTAKE; WILSON DISEASE;

EID: 79551702074     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881387     Document Type: Review

References (109)

1. Scherlock S, Dooley J: Hepatic encephalopathy. Diseases of the Liver and Biliary System. Oxford: Blackwell Scientific, 1993; 86-101
2. Zieve L: Hepatic encephalopathy. Disease of the Liver. Philadelphia, Pennsylvania: Lippincott, 1987; 925-48
3. Gines P, Quintero E, Arroyo V et al: Compensated Cirrhosis: natural history and prognostic factors. Hepatology, 1987; 7: 122-28
4. Hazell AS, Butterworth RF: Hepatic encephalopathy: An update of pathophysiologic mechanisms. Proc Soc Exp Biol Med, 1999; 222: 99-112
5. Pomier LG: TIPS and hepatic encephalopathy. Semin Liver Dis, 1996; 16: 315-20
6. Rink CH, Haeting J, Nilius R: Prognosis assessment in patients with liver cirrhosis. Hepatogastroenterology, 1990; 37(II): A86, 514
7. Butterworth R: Alterations of neurotransmitter-related gene expression in human and experimental portal systemic encephalopathy. Metab Brain Dis, 1998; 13: 337-49
8. Butterworth R: Complications of cirrhosis III. Hepatic encephalopathy. J Hepatol, 2000; 32(1): 171-80
9. Nencki M, Pavlov J, Zaleski J: Ueber den ammoniakgehalt des blutes under der organe und die harnstoffbildug bei den saugethieren. Arch Exp Pathol Pharmakol, 1896; 37: 26-51
10. Shawcross DL, Damink SW, Butterworth RF, Jalan R: Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis, 2005; 20: 169-79
11. Clemmesen JO, Larsen FS, Kondrup J et al: Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology, 1999; 29: 648-53
12. Lockwood AH, Yap EWH, Wong WH: Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab, 1991; 11: 337-41
13. Albrecht J, Jones EA: Hepatic encephalopathy: Molecular mechanisms underlying the clinical syndrome. J Neurol Sci, 1999; 170: 138-46
14. Blei AT, Cordoba J: For the Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol, 2001; 96: 1968-76
15. Conn HO: The hepatic encephalopathies. Hepatic Encephalopathy: Syndromes and Therapies. Bloomington, Illinois: Medi-Ed Press, 1994; 13-26
16. Reddy PVB, Kakulavarapu V, Rama R, Norenberg MD: Inhibitors of the Mitochondrial Permeability Transition Reduce Ammonia - induced Cell Swelling in Cultured Astrocytes. J Neurosci Res, 2009; 87: 2677-85
17. th World Congress of Gastroenterology, Vienna, 1998. Hepatology, 2002; 35: 716-21
18. Santiago J, Munoz: Hepatic Encephalopathy. Med Clin N Am, 2008; 92: 795-812
19. Eroglu Y, Byrne W: Hepatic Encephalopathy. Emerg Med Clin N Am, 2009; 27: 401-14
20. th edition. Boston: Blackwll Sci; 1985
21. Weissenborn K: Diagnosis of subclinical hepatic encephalopathy. Med Sci Monit, 1999; 5(3): RA568-75
22. Kharbanda PS, Saraswat VA, Dhirman RK: Minimal hepatic encephalopathy: diagnosis by neuropsychological and neurophysiological methods. Indian J Gastroenterol, 2003; 22(2): 537-41
23. Ortiz M, Jacas C, Cordoba J: Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol, 2005; 4(1): s45-53
24. Chen S, Zhang L, Shi Y et al: Molecular adsorbent recirculating system: clinical experience in patients with liver failure based on hepatitis B in China. Liver, 2002; 22: 48-51
25. Gerber T, Schomerus H: Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs, 2000; 60: 1353-70
26. Sundaram V, Shaikh OS: Hepatic Encephalopathy: Pathophysiology and Emerging Therapies. Med Clin North Am, 2009; 93: 819-36
27. Ahlam M, Joe TRC: Ornithine transcarboylase deficiency presenting with acute liver failure. JIMD Short Reprt, 006 2006. Online
28. Hawkes ND, Thomas GA, Jurewicz A et al: Non-hepatic hyperammonemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J, 2001; 77: 717-22
29. Iyer RK, Yoo PK, Kern RM et al: Mouse model for human arginase deficiency. Mol Cell Biol, 2002; 22: 4491-98
30. Desjardins P, Bélanger M, Butterworth RF: Alterations in expression of genes coding for key astrocytic proteins in acute liver failure. J Neurosci Res, 2001; 66: 967-71
31. Wolpert E, Phillips SF, Summerskill WH: Ammonia production in the human colon: effects of cleansing, neomycin and acetohydroxamic acid. N Engl J Med, 1970; 283: 159-64
32. Weber FJ, Veach G: The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology, 1979; 77: 235-40
33. Shawcross D, Jalan R: Dispelling myths in the treatment of hepatic encephalopathy. Lancet, 2005; 365(9457): 431-33
34. Jalan R, Wright G, Davies NA, Hodges SJ: L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses, 2007; 69: 1064-69
35. Desjardins P, Rao KV, Michalak A et al: Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle. Metab Brain Dis, 1999; 14: 273-80
36. Raabe W: Synaptic transmission in ammonia intoxication. Neurochem Pathol, 1987; 6: 145-66
37. Takahashi K, Kameda H, Kataoka M: Ammonia potentiates GABAA response in dissociated rat cortical neurons. Neurosci Lett, 1993; 151: 51-54
38. Koffron A, Stein JA: Liver Transplantation: Indications, Pretransplant Evaluation, Surgery, and Posttransplant Complications. Med Clin N Am, 2008; 92: 861-88
39. Ott P, Larsen FS: Blood-brain barrier permeability to ammonia in liver failure: a critical reappraisal. Neurochem Int, 2004; 44: 185-98
40. Pedersen HR, Ring-Larsen H, Olsen NV, Larsen FS: Hyperammonemia acts synergistically with lipopolysaccharide in inducing changes in cerebral hemodynamics in rats anaesthetized with pentobarbital. J Hepatol, 2007; 47: 245-52
41. Ahl B, Weissenborn K, Van den Hoff J et al: Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis. Hepatology, 2004; 40: 73-79
42. Butterworth RF: Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices. Liver Int, 2003; 23(3): 5-9
43. Mookerjee RP, Dalton RN, Davies NA et al: Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl, 2007; 13: 400-5
44. Margulies JE, Thompson RC, Demetriou AA: Aquaporin-4 water channel is upregulated in the brain in fulminant hepatic failure. Hepatology, 1999; 30: 395A
45. Cagnin A, Taylor-Robinson SD, Forton DM, Banati RB: In vivo imaging of cerebral ''peripheral benzodiazepine binding sites'' in patients with hepatic encephalopathy. Gut, 2006; 55: 547-53
46. Rees CJ, Oppong K, Al Mardini H et al: Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut, 2000; 47: 571-74
47. Manoli I, Le H, Alesci S et al: Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells. FASEB J, 2005; 19: 1359-61
48. Guo Q, Sayeed I, Baronne LM et al: Progesterone administration modulates AQP4 expression and edema after traumatic brain injury in male rats. Exp Neurol, 2006;198: 469-78
49. Sawara K, Desjardins P, Chatauret N et al: Alterations in expression of genes coding for proteins of the neurovascular unit in ischemic liver failure. Neurochem Int, 2009; 55: 119-23
50. Ahboucha S, Butterworth RF: The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. Neurochem Int, 2008; 52: 575-87
51. Bélanger M, Asashima T, Ohtsuki S et al: Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Neurochem Int, 2007; 50: 95-101
52. Fessel JN, Conn HO: An analysis of the causes and prevention of hepatic coma. Gastroenterology, 1972; 62: 191
53. Bresci G, Parisi G, Banti S: Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med, 1993; 2: 414-16
54. Cash WJ, McConville P, McDermott E et al: Current concepts in the assessment and treatment of Hepatic Encephalopathy. Q J Med, 2010; 103: 9-16
55. Córdoba J, López-Hellín J, Planas M et al: Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study. J Hepatol, 2004; 41: 38-43
56. Swart GR, van den Berg JW, van Vuure JK et al: Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. Clin Nutri, 1989; 8: 329-36
57. Bianchi GP, Marchesini G, Fabbri A et al: Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomised cross-over comparison. J Intern Med, 1993; 223: 385-92
58. Riordan SM, Williams R: Treatment of hepatic encephalopathy. N Engl J Med, 1997; 337: 473-79
59. Tozun N: Influence of the metabolic complications of liver cirrhosis on dietary intake. Med Sci Monit, 2000; 6(6): RA1223-26
60. Als-Nielsen B, Gluud L, Gluud C: Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev, 2004; 2: CD003044
61. Prasad S, Dhiman RK, Duseja A et al: Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology, 2007; 45: 549-59
62. Bass N, Mullen K, Sigal S et al: Rifaximin is effective in maintaining remission in hepatice encephalopathy: Results of a large, randomised, placebo-controlled trial. J Hepatol, 2009; 50(I): S53
63. Dhiman RK, Sawhney MS, Chawla YK et al: Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci, 2000; 45: 1549-52
64. Kato M, Hughes RD, Keaays RT, Williams R: Electron microscopic study of brain capillaries in cerebral edema from fulminant hepatic failure. Hepatology, 1992; 15: 1060-66
65. Conn HO, Leevy CM, Vlahcevic ZR et al: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology, 1977; 72: 573-83
66. Morgan MH, Read AE, Speller DC: Treatment of hepatic encephalopathy with metronidazole. Gut, 1982; 23: 1-7
67. Basu P, Rayapudi K, Estevez J, Brown RS: A pilot study utilizing nitaazoxanide for hepatic encephalopathy in chronic liver failure. San Francisco, CA. Hepatology, 2008; 48(l1): 1742
68. Hermanowska-Szpakowicz T, Zajkowska J, Grygorczuk S et al: The conservative management of encephalopathy and hepatic coma. Med Sci Monit, 2003; 9(2): 68-71
69. Liu Q, Duan ZP, Ha DK et al: Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology, 2004; 39: 1441-49
70. Acharya SK, Bhatia V, Sreenivas V et al: Efficacy of L-ornithine-L-aspartate in acute liver failure: a double blind, randomized, placebo-controlled study. Gastroenterology, 2009; 136: 2159-68
71. Kircheis G, Wettstein M, S vom Dahl, Haussinger D: Clinical efficacy of L-ornithine-L-aspartate in the management of Hepatic Encephalopathy. Metab Brain Dis, 2002; 17: 453-62
72. Jiang Q, Jiang XH, Zheng MH, Chen YP: L-ornithine-L-aspartate in the management of hepatic encephalopathy: A meta-analysis. J Gastrenterol Hepatol, 2009; 24: 9-14
73. Olde Damink SW, Jalan R, Redhead DN et al: Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPS. Hepatology, 2002; 36: 1163-71
74. Haag K, Lu S, Rossle M et al: The influence of TIPS on portal haemodynamics and liver function with respect to hepatic encephalopathy and survival. Hepatology, 1995; 22: 296A
75. Pomier LG, Giguere JF, Lavoie J et al: Clinical efficacy of benzodiazepine antagonist RO 15-1788 (flumanezil) in cirrhotic patients with hepatic coma: results of a randomised double-blind placebo-controlled crossover trial. Hepatology, 1994; 19: 32-37
76. Romero-Gomez M, Ramos-Guerrero R, Grande L et al: Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol, 2004; 41: 49-54
77. Ytrebo LM, Kristiansen RG, Maehre H et al: L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology, 2009; 50: 165-74
78. Therrien G, Rose C, Butterworth RF: Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat. Hepatology, 1997; 25: 551-56
79. Hiraishi M: The effect of oral adsorbent on surgically induced hepatic failure. Jpn J Surg, 1987; 17: 517-27
80. Gentile S, Guarino G, Romano M et al: A randomised controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol, 2005; 3: 184-91
81. Nicaise C, Prozzi D, Viaene E et al: Control of acute, chronic and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents. Hepatology, 2008; 48: 1184-92
82. Als-Nielsen B, Kjaergard LL, Gluud C: Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev, 2001; 4: CD002798
83. Gyr K, Meier R, Haussler J et al: Evaluation of the efficacy and safety of flumanezil in the treatment of portal systemic encephalopathy: A double blind, randomised, placebo controlled multicentre study. Gut, 1996; 39: 319-24
84. Uribe M, Farca A, Márquez MA et al: Treatment of chronic portal systemic encephalopathy with bromocriptine: A double-blind controlled trial. Gastroenterology, 1979; 76: 1347-51
85. Marchesini G, Fabbri A, Bianchi G et al: Zinc supplementation and amino-acid nitrogen metabolism in patients with advanced cirrhosis. Hepatology, 1996; 23: 1084-92
86. Rubik J, Prokurat S, Pawłowska J et al: Albumin dialysis (MARS)as a new supportive treatment in patients with hepatic encephalopathy. Med Sci Monit, 2003; 9(2): 77-81
87. Hassanein TI, Tofteng F, Brown RS Jr et al: Randomised controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology, 2007; 46: 1853-62
88. Steiner C, Mitzner S: Experiences with MARS liver support therapy in liver failure. Analysis of 176 patients of the international MARS registry. Liver, 2002; 22: 20-25
89. Stadlbauer V, Tauss J, Portugaller HR et al: Hepatic encephalopathy following transjugular intrahepatic portosystemic shunts (TIPS): Management with L-ornithine-L-aspartate and stent reduction. Metab Brain Dis, 2007; 22: 45-50
90. Toyonaga A, Oho K: Should BRTO be the first-line treatment for portosystemic encephaloapthy? Intern Med, 2001; 40: 677-78
91. th Ed. Philadelphia: Lippincott Williams & Wilkins, 2003; 2445-67
92. Todd Stravitz R, Kramer AH, Davern T et al: Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med, 2007; 35(11): 2498-508
93. Ferenci P: Hepatic encephalopathy. Bockus Gastroenterology, 5th Ed. Philadelphia: WB Saunders, 1995; 1998-2003
94. Koffron A, Stein JA: Liver Transplantation: Indications, Pretransplant Evaluation, Surgery, and Posttransplant Complications. Med Clin N Am, 2008; 92: 861-88
95. Schiodt FV, Atillasoy E, Shakil AO et al: Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg, 1999; 5: 29-34
96. Kawecki D, Chmura A, Pacholczyk M et al: Bacterial infections in the early period after liver transplantation: Etiological agents and their susceptibility. Med Sci Monit, 2009; 15(12): CR628-37
97. Habibullah CM, Syed IH, Qamar A, Taher-Uz Z: Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation, 1994; 58: 951-52
98. Dhawan A, Puppi J, Hughes RD, Mitry RR: Human hepatocyte transplantation: current experience and future challenges. Nat Rev Gastroenterol Hepatol, 2010; 7(5): 288-98
99. Dragon Y, Avraham Y: Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP activated kinase. FASEB J, 2007; 10: 2431-41
100. Erceg S, Monfort P, Hernandez-Viadel M et al: Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain. Brain Res, 2005; 1036: 115-21
101. Erceg S, Monfort P, Hernández-Viadel M et al: Oral administration of sildenafil restore learning ability in rats with hyperammonemia and with portcaval shunts. Hepatology, 2000; 541: 299-306
102. Canales JJ, Elayadi A, Errami M et al: Chronic hyperammonemia alters motor and neurochemical responses to activation of group I metabotropic glutamate receptors in the nucleus accumbens in rats in vivo. Neurobiol Dis, 2003; 14: 380-90
103. Shawcross D, Jalan R: The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci, 2005; 62: 2295-304
104. Ahboucha S, Jiang W, Chatauret N et al: Indomethacin improves locomotor deficit and reduces brain concentrations of neuroinhibitory steroids in rats following portcaval anastomosis. Neurogastroenterol Motil, 2008; 2: 949-57
105. Cauli O, Rodrigo R, Piedrafita B et al: Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology, 2007; 46: 514-19
106. Takahashi H, Koehler RC, Brusilow SW, Traystman RJ: Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic tats. Am J Physiol, 1991; 261: H825-29
107. Norenberg MD, Jayakumar AR, Rama Rao KV, Panickar KS: New concepts in the mechanism of ammonia-induced astrocyte swelling. Metab Brain Dis, 2007; 22: 219-34
108. Cordoba J, Blei AT: Hepatic encephalopathy. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins, 2003; 595-623
109. Rose C, Michalak A, Pannunzio M et al: Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure. Hepatology, 2000; 31: 872-77